Physician

Dilip B Viswanath, MD

According to 2025 Medicare claims, Dilip Viswanath, MD (NPI: 1528019262) practices cardiology in the Camden, NJ market, with the plurality of this provider's patient population coming from Gloucester, NJ. This provider's primary affiliated billing organization is CARDIOVASCULAR ASSOCIATES OF THE DELAWARE VALLEY,P A (NPI: 1366495632; TIN: 223321233) and primary practice location at 08080-4011.

Viswanath's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,255 traditional Medicare patients, billed 6,409 HCPCS/CPT codes, and received $482,239 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 6,036 prescription claims across 858 beneficiaries totaling $1,311,878 in drug costs, led by Eliquis (Apixaban). 2018 DME data shows 14 claims. Open Payments data shows 124 records totaling $454,885. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $440,861 to $1,311,878. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	3,173	14,517	$549,990
2016	3,627	16,241	$650,483
2017	3,579	10,551	$699,040
2018	3,129	9,647	$744,814
2019	2,883	7,958	$589,788
2020	2,367	5,516	$399,340
2021	2,640	6,475	$499,295
2022	2,718	6,415	$496,134
2023	2,327	6,037	$497,331
2024	2,255	6,409	$482,239

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	669	3,715	$440,861
2016	650	4,038	$616,351
2017	684	4,390	$618,336
2018	685	4,409	$770,749
2019	696	4,691	$853,548
2020	712	4,880	$955,430
2021	728	5,227	$992,588
2022	748	5,112	$1,126,119
2023	787	5,442	$1,206,467
2024	858	6,036	$1,311,878

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	14	$290
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	435	440	$99
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	608	866	$98
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	425	520	$14
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	643	927	$11
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	771	895	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	283	18,539	$348,350
Xarelto	Rivaroxaban	219	16,355	$290,902
Farxiga	Dapagliflozin Propanediol	120	8,280	$149,930
Entresto	Sacubitril/Valsartan	58	3,840	$84,693
Repatha Sureclick	Evolocumab	65	3,752	$70,261

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	118	$8,533	Janssen Pharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$446,352	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dilip B. Viswanath, MD?

Tedicare shows public-source Medicare data for Dilip B. Viswanath, MD (NPI 1528019262), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dilip B. Viswanath, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Dilip B. Viswanath, MD?

Dilip B. Viswanath, MD is linked to CARDIOVASCULAR ASSOCIATES OF THE DELAWARE VALLEY,P A (billing NPI 1366495632) in the available physician profile data.

Does Dilip B. Viswanath, MD have Open Payments data?

Dilip B. Viswanath, MD has 124 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.